Using advanced MRI techniques to differentiate between benign and malignant kidney masses
Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques
This study is testing advanced MRI techniques to see if they can help doctors tell the difference between harmless and harmful kidney masses, so patients can avoid unnecessary surgeries.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Cambridge Academic / other |
| Locations | 1 site (Cambridge, Cambridgeshire) |
| Trial ID | NCT06016075 on ClinicalTrials.gov |
What this trial studies
This study aims to develop non-invasive imaging techniques to better understand the biology of renal masses, both benign and malignant. It utilizes advanced MRI methods, including Hyperpolarised MRI, Sodium MRI, and Deuterium metabolic imaging, to acquire detailed imaging data from human tissues. Participants will receive injections of hyperpolarised 13C pyruvate or consume deuterated glucose, allowing researchers to monitor metabolic changes in the kidney masses. The goal is to optimize imaging protocols to reduce unnecessary surgeries and biopsies for patients with renal masses.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with radiologically suspected or pathologically confirmed benign or malignant renal masses.
Not a fit: Patients who are pregnant, breastfeeding, or have contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and reduce unnecessary treatments for patients with kidney masses.
How similar studies have performed: Other studies using advanced imaging techniques have shown promise, but this specific approach is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Over 18 years old * Able to and provide written informed consent to participate * If female, postmenopausal or if women of child bearing potential (WOCBP) using a suitable contraception * If male, using a suitable contraceptive method for the duration of the study * Radiologically suspected or pathologically confirmed benign or malignant renal masses, as determined by standard clinical practice * Capable of undergoing a minimum of one study visit Exclusion Criteria: * Contraindication or inability to tolerate MRI * Pregnant or actively breast-feeding woman * If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI safe at 3 T (researcher to confirm) * Clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators * Laboratory abnormalities that may impact on the study results * Any other significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators
Where this trial is running
Cambridge, Cambridgeshire
- University Department of Radiology — Cambridge, Cambridgeshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Ferdia A Gallagher, MD PhD — Principal Investigator
- Study coordinator: Ines Horvat-Menih, MD
- Email: ih357@cam.ac.uk
- Phone: +44 1223 767062
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.